Washington University School of Medicine in St. Louis will collaborate with the pharmaceutical companies AbbVie, Biogen, and Eli Lilly & Co. to investigate the buildup and clearance of tau protein in the brains of patients with Alzheimer’s disease.

Tau is abundant in the brain’s nerve cells, where it stabilizes the scaffold-like microtubules that play a critical role in transporting cargo within cells. But in Alzheimer’s disease as well as other “tauopathies,” such as progressive supranuclear palsy and frontotemporal dementia, clumps of tau protein are abnormally deposited in nerve cells in tangles. However, it remains unclear how tau clumps relate to the memory loss and cognitive decline seen in patients with Alzheimer’s, or how they correspond to the brain’s accumulation of amyloid beta, another hallmark of the disease.

The newly formed collaboration, called the tau SILK Consortium, will take advantage of a technique developed by Washington University colleagues Randall Bateman, MD, Chihiro Sato, PhD, and Nico Barthelemy, PhD, to monitor alterations in the rate at which tau is produced, released and cleared from the brain and its surrounding fluid in patients with Alzheimer’s disease.

The technique, called SILK (for Stable Isotope Labeling Kinetics) has been used to measure levels of amyloid beta production and clearance in spinal fluid. Such research has revealed that patients with Alzheimer’s have altered production and clearance of amyloid beta decades before symptoms of the disease become apparent.

To read more please visit https://medicine.wustl.edu/news/consortium-investigate-tau-buildup-alzheimers-disease/

Source: Washington University School of Medicine in St. Louis